NO20034740D0 - Anvendelse av galantamin for behandling av patologiske manifestasjoner i sentralnervesystemet grunnet forgiftning med psykotropiskesubstanser - Google Patents

Anvendelse av galantamin for behandling av patologiske manifestasjoner i sentralnervesystemet grunnet forgiftning med psykotropiskesubstanser

Info

Publication number
NO20034740D0
NO20034740D0 NO20034740A NO20034740A NO20034740D0 NO 20034740 D0 NO20034740 D0 NO 20034740D0 NO 20034740 A NO20034740 A NO 20034740A NO 20034740 A NO20034740 A NO 20034740A NO 20034740 D0 NO20034740 D0 NO 20034740D0
Authority
NO
Norway
Prior art keywords
psychotropic
treatment
central nervous
substances
poisoning
Prior art date
Application number
NO20034740A
Other languages
English (en)
Other versions
NO20034740L (no
Inventor
Klaus Opitz
Joachim Moormann
Thomas Hille
Frank Becher
Original Assignee
Hf Arzneimittelforsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7682409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20034740(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hf Arzneimittelforsch Gmbh filed Critical Hf Arzneimittelforsch Gmbh
Publication of NO20034740D0 publication Critical patent/NO20034740D0/no
Publication of NO20034740L publication Critical patent/NO20034740L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20034740A 2001-04-24 2003-10-23 Anvendelse av galantamin for behandling av patologiske manifestasjoner i sentralnervesystemet grunnet forgiftning med psykotropiskesubstanser NO20034740L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10119862A DE10119862A1 (de) 2001-04-24 2001-04-24 Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen
PCT/EP2002/004277 WO2002085370A1 (de) 2001-04-24 2002-04-18 Verwendung von galanthamin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzen

Publications (2)

Publication Number Publication Date
NO20034740D0 true NO20034740D0 (no) 2003-10-23
NO20034740L NO20034740L (no) 2003-10-23

Family

ID=7682409

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034740A NO20034740L (no) 2001-04-24 2003-10-23 Anvendelse av galantamin for behandling av patologiske manifestasjoner i sentralnervesystemet grunnet forgiftning med psykotropiskesubstanser

Country Status (27)

Country Link
US (1) US8207159B2 (no)
EP (1) EP1383507B1 (no)
JP (1) JP2004531533A (no)
KR (1) KR20040005934A (no)
CN (1) CN100400043C (no)
AR (1) AR033468A1 (no)
AT (1) ATE378052T1 (no)
AU (1) AU2002308148B2 (no)
BR (1) BR0209126A (no)
CA (1) CA2444818C (no)
CZ (1) CZ20032789A3 (no)
DE (2) DE10119862A1 (no)
DK (1) DK1383507T3 (no)
EA (1) EA200301135A1 (no)
ES (1) ES2296990T3 (no)
HK (1) HK1062401A1 (no)
HU (1) HUP0401123A3 (no)
IL (2) IL158382A0 (no)
MX (1) MXPA03009765A (no)
NO (1) NO20034740L (no)
NZ (1) NZ529004A (no)
PL (1) PL207525B1 (no)
PT (1) PT1383507E (no)
SK (1) SK287235B6 (no)
TW (1) TWI329512B (no)
WO (1) WO2002085370A1 (no)
ZA (1) ZA200308004B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603595B1 (en) * 2003-02-27 2010-11-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treatment of drug dependence
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
FR2930891B1 (fr) 2008-05-06 2010-09-24 Biocodex Composes anti-amnesiants et compositions pharmaceutiques les comprenant
EP2586436A1 (en) * 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor
WO2016187339A1 (en) * 2015-05-18 2016-11-24 Synaptec Development Llc GALANTAMINE CLEARANCE OF AMYLOIDß

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1193061B (de) 1961-12-20 1965-05-20 Vni Chimiko Pharmazewtitschesk Verfahren zur Gewinnung von Galanthamin-hydrobromid aus Pflanzen der Familie der Amaryllidaceen
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
DE3843239C1 (no) 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US5015645A (en) * 1989-10-19 1991-05-14 Ciba-Geigy Corporation Tetracyclic pyrrole lactam derivatives
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE19509663A1 (de) 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
WO1998007431A1 (en) * 1996-08-22 1998-02-26 New York University Cholinesterase inhibitors for treatment of parkinson's disease
US5932557A (en) * 1997-08-12 1999-08-03 Mustafa; S. Jamal Adenosine A1 receptor antisense oligonucleotide treatment of alcohol and marijuana-induced psychomotor impairments
EP1231877A4 (en) * 1999-11-04 2009-03-18 Xel Herbaceuticals TRANSDERMALE ADMINISTRATION OF HUPERZIN
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders

Also Published As

Publication number Publication date
SK287235B6 (sk) 2010-04-07
DK1383507T3 (da) 2008-03-17
CZ20032789A3 (en) 2004-05-12
NZ529004A (en) 2007-01-26
ZA200308004B (en) 2004-02-11
MXPA03009765A (es) 2005-04-19
WO2002085370A1 (de) 2002-10-31
IL158382A0 (en) 2004-05-12
AR033468A1 (es) 2003-12-17
HK1062401A1 (en) 2004-11-05
JP2004531533A (ja) 2004-10-14
DE50211207D1 (de) 2007-12-27
SK13152003A3 (sk) 2004-04-06
EP1383507A1 (de) 2004-01-28
CN100400043C (zh) 2008-07-09
IL158382A (en) 2009-09-01
CA2444818C (en) 2009-06-16
KR20040005934A (ko) 2004-01-16
EA200301135A1 (ru) 2004-04-29
NO20034740L (no) 2003-10-23
ES2296990T3 (es) 2008-05-01
US20040116406A1 (en) 2004-06-17
US8207159B2 (en) 2012-06-26
AU2002308148B2 (en) 2006-11-02
PL207525B1 (pl) 2010-12-31
HUP0401123A3 (en) 2008-01-28
BR0209126A (pt) 2004-07-27
CN1505516A (zh) 2004-06-16
PL366840A1 (en) 2005-02-07
DE10119862A1 (de) 2002-11-07
CA2444818A1 (en) 2002-10-31
TWI329512B (en) 2010-09-01
ATE378052T1 (de) 2007-11-15
PT1383507E (pt) 2008-02-20
HUP0401123A2 (hu) 2004-09-28
EP1383507B1 (de) 2007-11-14

Similar Documents

Publication Publication Date Title
FR13C0062I2 (fr) Compositions pharmaceutiques comprenant du dextromethorphan et de la quinidine pour traiter des troubles neurologiques
GEP20084325B (en) Purine compounds and uses thereof as cannabinoid receptor ligandspurine compounds and uses thereof as cannabinoid receptor ligands
TW200531680A (en) Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
CY1110391T1 (el) Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους
BR0308290A (pt) Tratamento e prevenção de distúrbios inflamatórios
EP1900362A3 (en) Alfa-aminoamide derivatives useful in the treatment of addictive disorders
SE0203713D0 (sv) Novel compounds
CY1111206T1 (el) Βενζοθειοφαινια υποκατεστημενα με πιπεραζινη για την αγωγη διανοητικων διαταραχων
TNSN06053A1 (en) 6-substituted anilino purines as rtk inhibitors
DK1824493T3 (da) Oral suspension, der omfatter meloxicam
PA8597301A1 (es) Derivados de imidazol-4-il-etinil-piridina
SE0401465D0 (sv) New substituted piperdines as modulators of dopamine neurotransmission
NO20034740D0 (no) Anvendelse av galantamin for behandling av patologiske manifestasjoner i sentralnervesystemet grunnet forgiftning med psykotropiskesubstanser
NO953892D0 (no) Imidazolokinoksalinon-derivater som EAA-antagonister
MY135676A (en) Use of deoxypeganine for the treatment of pathological manifestations of the central nervous system based on intoxication with psychotropic substances
WO2007059445A3 (en) Synergistic combinations of norketamine and opioid analgesics
ATE398614T1 (de) Triazolverbindungen und ihre therapeutische verwendung
BR0312568A (pt) Composições gastrointestinais compreendendo derivados de gaba
MXPA06013945A (es) Piperidinas sustituidas, novedosas, como moduladores de la neurotransmision de dopamina.
RU2002122711A (ru) Способ профилактики вредного воздействия окружающей среды
ITRM20020130A0 (it) Mezzi diagnostici e terapeutici per la sindrome da ritardo mentale legata al cromosoma x.
TH71491A (th) สารประกอบชนิดใหม่
EA200601411A1 (ru) Новые ингибиторы глутаминилциклазы
UA84701C2 (ru) Замещенные индолы, способ их получения, их использования

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application